What is GW Pharmaceuticals?
GW Pharmaceuticals was founded in 1998 and listed on the AiM, a market of the London Stock Exchange, in June 2001. GW is licensed by the UK Home Office to work with a range of controlled drugs for medical research purposes. GW is a pharmaceutical group developing a portfolio of cannabinoid prescription medicines to meet patient needs in a wide range of therapeutic conditions. GW has assembled a team of over 100 scientists with extensive experience in developing both plant-based prescription pharmaceutical products and medicines containing controlled substances. GW maintains control over all aspects of the product development process – botanical research, cultivation, extraction, formulation into drug delivery technologies, clinical trials and regulatory affairs. The Group has a broad product portfolio and the Directors have identified certain key markets for its products including Multiple Sclerosis, neuropathic pain, and cancer Pain. GW’s lead product, Sativex®, received regulatory ap
